The long-term efficacy and tolerability of the new anti-inflammatory agent Zaltoprofen in rheumatoid arthritis

Current Medical Research and Opinion

Volumn 14, Issue 2, 1998, Pages 79-87

  Hatori, Masahito ^a   Kokubun, Shoichi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse drug reactions; Efficacy; Long term tolerability; NSAIDs; Rheumatoid arthritis; Zaltoprofen

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; ZALTOPROFEN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GRIP STRENGTH; HUMAN; LONG TERM CARE; MALE; MORNING STIFFNESS; MULTICENTER STUDY; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATIC DISEASE; SYMPTOM;

EID: 0031869088     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999809113346     Document Type: Article

References (30)

1. Armstrong, C. P. and Blower, A. L. (1987). Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut, 28, 527-532.
2. Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., Medsger Jr., T. A., Mitchell, D. M., Neustadt, D. H., Pinals, R. S., Schaller, J. G., Sharp, J. T., Wilder, R. L. and Hunder, G. G. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum., 31, 315-324.
3. Bijlsma, A. (1978). The long-term efficacy and tolerability of voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis. Scand. J. Rheumatology, Suppl 22, 74-80.
4. Burch, F. X. (1985), Evaluation of the safety of isoxicam. Am. J. Med., 79, 28-32.
5. Ciccolunghi, S. N., Chaudri, H. A. and Schubiger, B. I. (1979). How long should long be? Long-term trials in rheumatic diseases. Annals Rheum. Dis., 38, 155-160.
6. Ciccolunghi, S. N., Chaudri, H. A., Schubiger, B. I. and Reddrop, R. (1978). Report on a long-term tolerability study of up to two years with diclofenac sodium (voltaren). Scand. J. Rheumatology, Suppl 22, 86-96.
7. Fries, J. F., Miller, S. R., Spitz, P. W., Williams, C. A., Hubert, H. B. and Bloch, D. A. (1989). Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology, 96, 647-655.
8. Graham, D. Y. and Smith, J. L. (1988). Gastroduodenal complications of chronic NSAID therapy. Am. J. Gastroenterol., 83, 1081-1084.
9. Griffin, M. R., Ray, W. A. and Schaffner, W. (1988). Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann. Intern. Med., 109, 359-363.
10. Hatori, M., Sakurai, M., Kokubun, S. and Rijal, K. P. (1990). Piroxicam suppositories in the treatment of osteoarthritis of the knee joint. Clin. Ther., 12, 227-229.
11. Hatori, M., Sakurai, M. and Miyasaka, Y. (1992). Clinical evaluation of BPA A patch in the treatment of extremity trauma. Contemp. Orthop., 24, 721-727.
12. Hatori, M. and Kokubun, S. (1997). Clinical evaluation of indomethacin-containing patches for osteoarthritis and extremity trauma. Curr. Med. Res. Opin., 13, 511-515.
13. Huskisson, E. C., Ghozlan, R., Kurthen, R., Deigner, F. L. and Bluhmk, E. (1996). A long-term study to evaluate the safety and efficiency of meloxicam therapy in patients with rheumatoid arthritis. Br. J. Rheumatol., 35 (Suppl 1), 29-34.
14. Ishizaki, T., Kubota, K., Echizen, H., Horai, Y. and Chiba, K. (1992). Non-steroidal anti-inflammatory agent, phase I clinical trial with CN-100-single and repeated oral administration study. Rheumati, 32, 12-18. (In Japanese.)
15. Jallad, N. S., Cattan, A. and Weidler, D. J. (1993) Efficacy of misoprostol in controlling indomethacin induced fecal blood loss in arthritic patients. J. Clin. Pharmacol., 31, 376-381.
16. Kameyama, T., Nabeshima, T., Yamada, S. and Sato, M. (1987). Analgesic and antiinflammatory effects of 2-(10,11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl) propionic acid in rat and mouse. Arzneim. -Forsch./ Drug Res., 37, 19-26.
17. Lansbury, J., Baier, H. N. and McCracken, S. (1962). Statistical study of variation in systemic and articular indexes. Arth. Rheumat., 5, 445-456.
18. Lockie, L. M. (1986). Tolerability and efficacy of long-term daily administration of indomethacin for moderate to severe chronic arthritic disorders. Clin. Ther., 8, 398-405.
19. Pasero, G., Marcolongo, R., Serni, U., Parnham, M. J. and Ferrer, F. (1995). A multicentre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. Curr. Med. Res. Opin., 13, 305-315.
20. Pincus, T., Marcum, S. B., Callahan, L. F., Adams, R. F., Barber, J., Barth, W. F., Gordon, G. V., Huston, J. W., Polk, J. R., Whelton, J. C. and Brooks, R. H. (1992). Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J. Rheumatol., 19, 1874-1884.
21. Solomon, L. and Abrams, G. (1974). Voltaren in the treatment of rheumatoid arthritis. S. Afr. Med. J., 48, 949-952.
22. Steinbrocker, O., Traeger, C. H. and Batterman, R. C. (1949). Therapeutic criteria in rheumatoid arthritis. JAMA, 140, 659-662.
23. Swift, G. L., Arnold, J., Williams, G. T., Williams, B. D., Rhodes, J. and Khan, F. (1992). Risk of ulceration with long-term indomethacin: endoscopic and histological changes in upper gastro-intestinal mucosa. Digestion, 53, 88-93.
24. Tsurumi, K., Kyuki, K., Niwa, M., Kokuba, S. and Fujimura, H. (1986). Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro10-oxodibenzo [b,f] thiepin-2-yl) propionic acid. First communication: inhibitory effects on rat paw edema. Arzneim. -Forsch./Drug Res., 36, 1796-1800.
25. Tsurumi, K., Kyuki, K., Niwa, M., Mibu, H. and Fujimura, H. (1986). Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl) propionic acid. Second communication: inhibitory effects on acute inflammation and prostaglandin-related reactions. Arzneim. -Forsch./Drug Res., 36, 1801-1805.
26. Tsurumi, K., Mibu, H., Okada, K., Hasegawa, J. and Fujimura, H. (1986). Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl) propionic acid. Third communication: inhibitory effects on leucocyte emigration and proliferation of granulation. Arzneim. -Forsch./Drug Res., 36, 1806-1809.
27. Tsurumi, K., Kokuba, S., Okada, K., Yanagihara, M. and Fujimura, H. (1986). Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl) propionic acid. Fourth communication: inhibitory effects on rat adjuvant arthritis. Arzneim. -Forsch./Drug Res., 36, 1810-1817.
28. Tsurumi, K., Kyuki, K., Yanagihara, M., Hasegawa, J. and Fujimura, H. (1986). Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl) propionic acid. Fifth communication: antiplatelet effect of the drug and antiinflammatory effect of its main metabolite. Arzneim. -Forsch./Drug Res., 36, 1818-1822.
29. Wijnands, M., van Kiel, P., van't Hof, M., Gribnau, F. and van de Putte, L. (1991). Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: A prospective drug survival study. J. Rheum., 18, 184-187.
30. Yoshizawa, H. and Nobunaga, T. (1991). Early phase II clinical study of CN-100, new antiinflammatory agents on rheumatoid arthritis. Yakuri to Tiryo, 19, 557-569. (In Japanese.)